SCHEMBL4241702

SCHEMBL4241702

Cc1onc(-c2ccccc2)c1C(=O)N1CCC(Nc2cnc3ccccc3n2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
HTT P42858 1/20 0.55
HCRTR1 O43613 2/20 0.54
HCRTR2 O43614 2/20 0.54
USP2 O75604 1/20 0.54
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
LMNA P02545 3/20 0.52
TSHR P16473 2/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.49
NPC1 O15118 1/20 0.48
GAA P10253 1/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
MMP7 P09237 1/20 0.46
MMP9 P14780 1/20 0.46
MMP13 P45452 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241696 1.00 SMN1; SMN2 (0.55) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL8224727 0.91 HCRTR1 (0.51) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL4243256 0.91 HCRTR1 (0.51) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL4243262 0.91 HCRTR1 (0.51) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL4238687 0.91 HCRTR1 (0.54) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL4238683 0.91 HCRTR1 (0.54) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL3543194 0.82 KMT2A (0.65) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL8224531 0.79 HCRTR1 (0.52) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL1463236 0.78 NPSR1 (0.55) SMN1; SMN2HTTHCRTR1HCRTR2USP2
SCHEMBL1463238 0.78 NPSR1 (0.55) SMN1; SMN2HTTHCRTR1HCRTR2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, MTNR1A SMN1; SMN2 2577/4885HTT 317/4885HCRTR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.